Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance — AACR 2026
Presented at AACR; demonstrates GenoPredicta’s whole-genome sequencing from as few as ~50 circulating tumor cells, with 100% concordance to bone marrow and FISH and detection of subclonal, resistance-associated alterations from blood.
Related Resources
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Highlights:
•EloLenDex is associated with 4-year PFS of 89% in patients with high-risk SMM
•Immune reactivity, post-therapy immune normalization are associated with longer PFS
•Higher abundance of GZMK+ cytotoxic T cells is associated with longer PFS
•Blood-based immune profiling detects immune dysregulation associated with disease
GenoPredicta™ Specimen Collection Instructions
Step-by-step prep, collection, packaging, and shipping instructions for blood or bone marrow samples.
A novel clinical assay comprehensively characterizes myeloma genomes from bone marrow and peripheral blood
Presented at the International Myeloma Society congress, demonstrating high analytical concordance between blood and bone marrow and confirming the platform’s readiness for routine clinical use.
Predicta Newsletter
Enter your email address to subscribe.
Enter Email Address:
Predicta Biosciences
750 Main Street, Lab 413
Cambridge, MA 02139